Description of Invention:
Members of the inhibitor of growth (ING) family of tumor suppressor genes are involved in the regulation of diverse processes including cell cycle progression, apoptosis, and DNA repair as important cofactors of p53. ING members contain a highly evolutionary conserved sequence common in chromatin-regulating proteins, and there are overlapping functions between ING family members in negative regulation of cell growth as well as a dependent regulation between various ING members and p53.
Available for licensing are compositions for new tumor suppressor designated p28ING5, p33ING2, and p47ING3 (pING). Overexpression of these proteins has been shown to inhibit cell proliferation in human cancer cells lines, and these characteristics suggest that they may have important implications in cancer diagnosis and therapy. These compositions include nucleic acids, polypeptides, and antibodies that specifically bind to their respective ING members. Also claimed are cancer diagnostic and treatment methods.
Applications:
Methods to treat and diagnose cancer with pING compositions.
Methods to identify pING modulating agents.
Research tool to study cell cycle regulation and p53 pathways.
pING compositions.
Market:
Cancer is the second leading cause of death in United States.
An estimated 600,000 deaths caused by cancer in 2006.
Development Status:
The technology is currently in the pre-clinical stage of development.
Patent Status:
DHHS Reference No. E-272-1998/0 --
U.S. Patent No. 6,790,948 issued 14 Sep 2004
U.S. Patent No. 7,431,926 issued 07 Oct 2008
U.S. Patent Application No. 12/203,836 filed 08 Sep 2008
Related Technologies: DHHS Reference No. E-254-1999/0 --
U.S. Patent No. 7,335,749 issued 26 Feb 2008
U.S. Patent Application No. 11/962,906 filed 21 Dec 2007
DHHS Reference No. E-300-2001/0 --
U.S. Patent No. 7,432,349 issued 07 Oct 2008
U.S. Patent Application No. 12/198,897 filed 27 Aug 2008
Relevant Publication:
T Okano et al. Alterations in novel candidate tumor suppressor genes, ING1 and ING2 in human lung cancer. Oncol Rep. 2006 Mar;15(3):545-549. [PubMed abs]
H Kataoka et al. ING1 represses transcription by direct DNA binding and through effects on p53. Cancer Res. 2003 Sep 15;63(18):5785-5792. [PubMed abs]
M Nagashima et al. A novel PHD-finger motif protein, p47ING3, modulates p53-mediated transcription, cell cycle control, and apoptosis. Oncogene. 2003 Jan 23;22(3):343-350. [PubMed abs]
M Nagashima et al. DNA damage-inducible gene p33ING2 negatively regulates cell proliferation through acetylation of p53. Proc Natl Acad Sci USA. 2001 Aug 14;98 (17):9671-9676. [PubMed abs]
Licensing Status: Available for exclusive or non-exclusive licensing.
Portfolios: Devices/Instrumentation Cancer
Cancer -Diagnostics-In Vitro Cancer -Therapeutics-Immunoconjugates Devices/Instrumentation-Therapeutics-Other Devices/Instrumentation-Research Materials-Methods of Using Research Tools Devices/Instrumentation-Research Materials-Biologicals and Chemicals Cancer -Diagnostics Cancer -Therapeutics Cancer -Research Materials Cancer -Other Devices/Instrumentation-Therapeutics Devices/Instrumentation-Research Materials
For Additional Information Please Contact: Jennifer Wong
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-4633
Email: wongje@mail.nih.gov
Fax: (301)402-0220
